<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02219178</url>
  </required_header>
  <id_info>
    <org_study_id>CTRIAL-IE (ICORG) 13-17</org_study_id>
    <secondary_id>2013-005008-32</secondary_id>
    <nct_id>NCT02219178</nct_id>
  </id_info>
  <brief_title>Study of the Efficacy and Safety of RsqVD Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma</brief_title>
  <official_title>A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib, and Dexamethasone Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer Trials Ireland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cancer Trials Ireland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the overall response rate after 4 cycles and the best response to&#xD;
      induction therapy with combination of lenalidomide, subcutaneous bortezomib, and&#xD;
      dexamethasone (RsqVD) in patients with newly diagnosed multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">April 2020</completion_date>
  <primary_completion_date type="Actual">October 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the overall response rate (ORR) after 4 induction cycles</measure>
    <time_frame>After 4 cycles (84 days)</time_frame>
    <description>To evaluate the overall response rate (ORR) after 4 induction cycles and the best response to induction therapy with the combination of lenalidomide, subcutaneous (SQ) bortezomib, and dexamethasone (RsqVD) in patients with newly diagnosed multiple myeloma.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>a) To evaluate the rate and severity of Peripheral Neuropathy (PN) of SQ bortezomib in combination with lenalidomide, and dexamethasone after the 4th and after the final cycle of induction therapy.</measure>
    <time_frame>After 4 cycles (84 days)</time_frame>
    <description>Evaluate the rate and severity of Peripheral Neuropathy of SQ bortezomib in combination with lenalidomide, and dexamethasone after the 4th and after the final cycle of induction therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression of disease</measure>
    <time_frame>Duration of the study, expected to be approximately 3 years</time_frame>
    <description>Evaluate the time to progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Duration of the study, expected to be approximately 3 years</time_frame>
    <description>Evaluate progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Duration of the study, expected to be approximately 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>RsqVD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral lenalidomide 25mg days 1 - 14 of 21 day schedule Subcutaneous bortezomib 1.3mg/m2 days 1, 4, 8, 11 of 21 day schedule Oral dexamethasone 20mg on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 day schedule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lenalidomide</intervention_name>
    <description>25mg days 1 - 14 of 21 day schedule</description>
    <arm_group_label>RsqVD</arm_group_label>
    <other_name>Revlimid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Subcutaneous bortezomib</intervention_name>
    <description>1.3mg/m2 days 1, 4, 8, 11 of 21 day schedule</description>
    <arm_group_label>RsqVD</arm_group_label>
    <other_name>Velcade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>20mg on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 day schedule</description>
    <arm_group_label>RsqVD</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participants must have a diagnosis of symptomatic MM, according to International&#xD;
             Myeloma Foundation 2003 Diagnostic Criteria:&#xD;
&#xD;
               -  Clonal plasma cells &gt; 10% on bone marrow biopsy&#xD;
&#xD;
               -  A monoclonal protein (paraprotein) in either serum or urine ( except in the cases&#xD;
                  of non-secretory myeloma).&#xD;
&#xD;
             If no monoclonal protein is detected (non-secretory disease), then ≥ 30% monoclonal&#xD;
             bone marrow plasma cells and/or a biopsy-proven plasmacytoma required.&#xD;
&#xD;
               -  Evidence of end-organ damage felt related to the plasma cell disorder related&#xD;
                  organ or tissue impairment (ROTI), commonly referred to by the acronym 'CRAB':&#xD;
&#xD;
                    -  Hypercalcaemia: serum calcium (corrected for albumin) &gt;&#xD;
                       10.5mg/sL/&gt;2.65mmol/L or upper limit of normal&#xD;
&#xD;
                    -  Renal insufficiency defined as serum creatinine &gt; 2mg/sL/177μmol/L&#xD;
&#xD;
                    -  Anaemia: Normochromic, normocytic with a haemoglobin value &gt; 2g/dL below the&#xD;
                       lower limit of normal or a haemoglobin &lt; 10g/dL&#xD;
&#xD;
                    -  Bone lesions (lytic lesions, severe osteopenia or pathologic fractures) as&#xD;
                       shown by CT scan and/or skeletal survey&#xD;
&#xD;
          2. Patient has received no prior treatment with any systemic therapy for the treatment of&#xD;
             multiple myeloma.&#xD;
&#xD;
               -  Prior treatment of hypercalcaemia or spinal cord compression with corticosteroids&#xD;
                  does not disqualify the patient (the dose should not exceed the equivalent of 160&#xD;
                  mg of dexamethasone in a 2 week period)&#xD;
&#xD;
               -  Bisphosphonates are permitted&#xD;
&#xD;
               -  Patients treated with local radiotherapy with or without concomitant exposure to&#xD;
                  steroids, for pain control or management of cord/nerve root compression, are&#xD;
                  eligible. Two weeks must have lapsed since last date of radiotherapy, which is&#xD;
                  recommended to be a limited field. Patients who require concurrent radiotherapy&#xD;
                  should have entry to the protocol deferred until the radiotherapy is completed&#xD;
                  and 2 weeks have passed since the last date of therapy.&#xD;
&#xD;
          3. Voluntary written informed consent before performance of any study-related procedure&#xD;
             not part of normal medical care, with the understanding that consent may be withdrawn&#xD;
             by the subject at any time without prejudice to future medical care&#xD;
&#xD;
          4. Age ≥ 18 years at the time of signing Informed Consent&#xD;
&#xD;
          5. Females of reproductive potential must adhere to the scheduled pregnancy testing as&#xD;
             required in the Lenalidomide Pregnancy Prevention Risk Management Plan. Females of&#xD;
             childbearing potential (FCBP) must have a negative serum or urine pregnancy test with&#xD;
             a sensitivity of at least 50 mlU/mL 10 to14 days prior to therapy and repeated again&#xD;
             within 24 hours prior to prescribing lenalidomide for Cycle 1 (prescriptions must be&#xD;
             filled within 7 days as required by Lenalidomide Pregnancy Prevention Risk Management&#xD;
             Plan) and must either commit to complete abstinence from heterosexual contact or begin&#xD;
             TWO acceptable methods of birth control, one highly effective method and one&#xD;
             additional effective (barrier) method, AT THE SAME TIME, at least 28 days before she&#xD;
             starts taking lenalidomide. FCBP must also agree to ongoing pregnancy testing. Men&#xD;
             must practice complete abstinence or agree to use a condom during sexual contact with&#xD;
             a FCBP even if they have had a successful vasectomy. All study participants must be&#xD;
             registered into the mandatory Lenalidomide Pregnancy Prevention Risk Management Plan,&#xD;
             and be willing and able to comply with the requirements of the Lenalidomide Pregnancy&#xD;
             Prevention Risk Management Plan.*A female of childbearing potential is a sexually&#xD;
             mature female who: 1) has not undergone a hysterectomy (the surgical removal of the&#xD;
             uterus) or bilateral oophorectomy (the surgical removal of both ovaries) or 2) has not&#xD;
             been naturally postmenopausal (amenorrhea following cancer therapy does not rule out&#xD;
             childbearing potential) for at least 24 consecutive months (i.e. has had menses at any&#xD;
             time during the preceding 24 consecutive months)&#xD;
&#xD;
          6. All necessary baseline studies for determining eligibility must be obtained within 21&#xD;
             days prior to enrolment&#xD;
&#xD;
          7. Subject has an ECOG performance status of &lt; 2 or Karnofsky performance status of ≥ 60&#xD;
             (Appendix E).&#xD;
&#xD;
          8. Subject must be able to adhere to the study visit schedule and other protocol&#xD;
             requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient has ≥ Grade 2 peripheral neuropathy on clinical examination within 14 days&#xD;
             before enrolment&#xD;
&#xD;
          2. Renal insufficiency (serum creatinine levels &gt; 2.5 mg/dL/221μmol/L, calculated&#xD;
             creatinine clearance with Cockcroft-Gault formula (see Appendix G) &lt; 45 ml/min)&#xD;
&#xD;
          3. Subjects with evidence of mucosal or internal bleeding and/or platelet refractory&#xD;
             (i.e. unable to maintain a platelet count 50,000 cells/mm3)&#xD;
&#xD;
          4. Subjects with an absolute neutrophil count (ANC) &lt; 1000 cells/mm3. Growth factors may&#xD;
             not be used to meet ANC eligibility criteria&#xD;
&#xD;
          5. Subjects with a haemoglobin &lt; 8.0 g/dL&#xD;
&#xD;
          6. AST (SGOT) and ALT (SGPT) &gt; 2 x ULN, bilirubin levels 1.5 ULN&#xD;
&#xD;
          7. Concomitant therapy medications that include corticosteroids (except as indicated in&#xD;
             inclusion criteria)&#xD;
&#xD;
          8. Myocardial infarction within 6 months prior to enrolment or has New York Heart&#xD;
             Association (NYHA) Class III or IV heart failure (Appendix G), uncontrolled angina,&#xD;
             severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute&#xD;
             ischemia or active conduction system abnormalities&#xD;
&#xD;
          9. Clinically relevant active infection requiring treatment (antibiotics, antivirals,&#xD;
             antifungals)&#xD;
&#xD;
         10. Any serious co-morbid condition, including laboratory abnormalities, that in the&#xD;
             opinion of the Investigator places the subject at unacceptable risk if he/she were to&#xD;
             participate in the study.&#xD;
&#xD;
         11. Female subject is pregnant or breast-feeding&#xD;
&#xD;
         12. Serious psychiatric illness or addiction likely to interfere with participation in&#xD;
             this clinical study&#xD;
&#xD;
         13. Uncontrolled diabetes mellitus&#xD;
&#xD;
         14. Contraindication to any required concomitant drugs or supportive therapies including&#xD;
             hypersensitivity to all anticoagulation and antiplatelet options or hypersensitivity&#xD;
             to acyclovir or similar anti-viral drug. History of allergic reaction/hypersensitivity&#xD;
             attributed to compounds containing boron, mannitol, polysorbate 80 or sodium citrate&#xD;
             dehydrate&#xD;
&#xD;
         15. POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly,&#xD;
             endocrinopathy, monoclonal protein (M-protein) and skin changes)&#xD;
&#xD;
         16. Known seropositive for or active HIV infection or active hepatitis B or C viral&#xD;
             infection. Patients who are seropositive because of hepatitis B virus vaccine are&#xD;
             eligible&#xD;
&#xD;
         17. Known intolerance to steroid therapy&#xD;
&#xD;
         18. Patient has hypersensitivity to bortezomib, boron, or mannitol&#xD;
&#xD;
         19. Diagnosed or treated for another malignancy within 2 years of enrolment, with the&#xD;
             exception of complete resection of basal cell carcinoma or squamous cell carcinoma of&#xD;
             the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy&#xD;
&#xD;
         20. Participation in clinical trials with other anti-myeloma investigational agents not&#xD;
             included in this trial, within 14 days of the start of this trial and throughout the&#xD;
             duration of this trial&#xD;
&#xD;
         21. Radiation therapy within 2 weeks before randomization. Enrolment of subjects who&#xD;
             require concurrent radiotherapy (which must be localized in its field size) should be&#xD;
             deferred until the radiotherapy is completed and 2 weeks have elapsed since the last&#xD;
             date of therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter O'Gorman, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mater Misericordiae University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Waterford</name>
      <address>
        <city>Waterford</city>
        <state>Co Waterford</state>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cork University Hospital</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Misericordiae University Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St James's Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Galway</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Limerick</name>
      <address>
        <city>Limerick</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midlands Regional Hospital</name>
      <address>
        <city>Tullamore</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ireland</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 11, 2014</study_first_submitted>
  <study_first_submitted_qc>August 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2014</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

